SnapShot: Cancer Immunotherapy with Oncolytic Viruses | Zendy

Shashi Gujar | Zendy; John C. Bell | Zendy; JeanSimon Diallo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Author(s) -

Shashi Gujar,

John C. Bell,

JeanSimon Diallo

Publication year - 2019

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2019.01.051

Subject(s) - oncolytic virus , biology , immune system , immunotherapy , cancer immunotherapy , immune checkpoint , blockade , cancer , immunology , cancer research , cancer cell , genetics , receptor

Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research